Skip To Main Content
C-C. Lin on Muck Rack

C-C. Lin

As seen in: Annals of Oncology, European Urology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with C-C.

Contact C-C., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Intravesical instillation of epidermal growth factor could ameliorate urothelial inflammation and down-regulate oxidative stress in rats with LPS-induced interstitial cystitis

|
By C.H. Yang, M-C. Tung, Y-C. Ou, C-C. Lin
| European Urology Verified
This site can’t provide a secure connection acw.secure.jbs.elsevierhealth.com uses an unsupported protocol.
Open in Who Shared View Duplicates (332) Issue with article?

407P Pembrolizumab Expanded Access Program (EAP) in Taiwan for patients with progressive advanced melanoma after prior ipilimumab treatment

|
By C-C. Lin, C-K. Yang, J-H. Liu, T-C. Liu
| Annals of Oncology Verified
407P Pembrolizumab Expanded Access Program (EAP) in Taiwan for patients with progressive advanced melanoma after prior ipilimumab treatment C-K. Yang1, J-H. Liu2, C-C. Lin3, T-C. Liu4, P-T. Cheng5, C-Y. Lin6, H-T. Hu7, C-R. Cao8, W-T. Huang8, L-P. Chen9 and W-C.
Open in Who Shared Issue with article?

2OPhase 1 study of ramucirumab (R) plus durvalumab (D) in patients (pts) with locally advanced and unresectable or metastatic gastrointestinal or thoracic malignancies (NCT02572687); Phase 1a results

|
By T. Golan, Tel Hashomer, C-C. Lin, J. Corral
| Annals of Oncology Verified
Aim/Background: Simultaneously targeting angiogenesis and immunosuppression demonstrates a synergistic antitumor effect in preclinical models. Preliminary safety results from the phase 1a portion of this study are reported for the NSCLC, G/GEJ, and HCC cohorts. Methods: Eligible pts with advanced NSCLC, G/GEJ, or HCC who progressed on prior systemic therapy were enrolled.
Open in Who Shared Issue with article?
See all 3 articles